Published in Surgery Litigation and Law Weekly, October 13th, 2006
The test, known as OncoPlan, is already commercially available, and studies have shown that it can predict the aggressiveness of the patient's tumor and the relative risk of disease recurrence following surgery in breast, colon and gastric cancers. Now, researchers in the U.S. and Canada have studied whether it also can help identify breast cancer patients who would benefit most from...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly